Skip to main content
SpringerLink
Log in

Coagulation studies and platelet function after somatostatin infusion

Blutgerinnung und Thrombozytenfunktionen nach Infusion von Somatostatin

  • Originalien
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Zusammenfassung

Die Beeinflussung verschiedener Haemostaseparameter beim Menschen durch Kurzund Langzeit-Anwendung von Somatostatin (GIF) wurde untersucht. Das in der Studie eingesetzte Dosierungsschema bestand aus einer intravenösen Bolusinjektion von 250 µg GIF und einer anschließenden Dauerinfusion von 250 µg GIF/h. Bei 5 gesunden, freiwilligen Probanden war nach Beendigung einer Kurzzeittherapie über 3 h ein statistisch signifikanter Abfall der Thrombozytenzahl und eine Beeinträchtigung der Thrombozytenfunktion nachweisbar. Die Veränderungen lagen jedoch innerhalb des physiologischen Normalbereiches und waren innerhalb von 2 h nach Infusionsende voll reversibel. Andere Parameter (Blutungszeit, Thromboplastinzeit und Partialthromboplastinzeit, Fibrinogen, Fibrinogen/Fibrinspaltprodukte, Blutgerinnungsfaktor XIII, Äthanoltest) wurden nicht beeinflußt. Bei 2 Patienten mit Magenblutung bzw. persistierender Amylasämie wurde die Somatostatin-Behandlung über 67 bzw. 120 h durchgeführt. Ein klinisch relevanter Haemostasedefekt war bei Therapieende labordiagnostisch nicht erkennbar. Im Fall des Patienten mit Magenblutung kam es vielmehr 60 min nach Beginn der Therapie zum Sistieren der Haemorrhagie.

Die Untersuchungen haben gezeigt, daß nach Anwendung von Somatostatin beim Menschen unter Verwendung des angegebenen Dosierungsschemas weder klinische noch labordiagnostische Hinweise bestehen, die die Annahme einer klinisch relevanten, iatrogen-induzierten haemorrhagischen Diathese rechtfertigen.

Summary

The effect of short- and long-term somatostatin (GIF) administration on haemostatic function in man was investigated. The dosage programme applied in this study was 250 µg GIF as a bolus injection and 250 µg GIF/h by way of infusion. In five healthy volunteers a short-term (3 h) treatment resulted in a statistically significant drop of platelet count and impairment of platelet aggregation at the end of infusion. However, these changes were within the physiologically normal range and disappeared after two hours on all subjects. Other parameters such as bleeding time, thromboplastin and partial thromboplastin time, fibrinogen, fibrin/fibrinogen split products, plasma factor XIII, ethanol gelation test were not affected. In two patients with gastric haemorrhage and persistent amylasaemia a 67 or 120-h treatment induced no remarkable haemostatic defect. By contrast, peptic ulcer bleeding in one patient stopped 60 min after starting the GIF infusion.

These studies indicated that somatostatin administration in man at the dosage programme used neither results in clinical evidence indicating bleeding tendency nor does it influence laboratory parameters in an apparent way.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Alford, F.P., Bloom, S.R., Nabarro, J.D.N.: Glucagon control of fasting glucose in man. LancetII, 974–976 (1974)

    Google Scholar 

  2. Arnold, R., Köberling, J., Track, N.S., Creutzfeldt, W.: Lowering of basal and stimulated serum immunoreactive gastrin and gastric secretion in patients with Zollinger-Ellison syndrome by somatostatin. 21. Symp. Dtsch. Ges. Endokrin. München, February 26–March 1, 1975. Acta endocr. (Kbh.) Suppl.193, 75 (1975)

    Google Scholar 

  3. Benker, G., Reinwein, D.: Somatostatin. Dtsch. med. Wschr.100, 961–964 (1975)

    PubMed  Google Scholar 

  4. Besser, G.M., Mortimer, C.H., Carr, D., Schally, A.V., Coy, D.V., Evered, D., Kastin, A.J., Tunbridge, W.M.G., Thorner, M.O., Hall, R.: Growth hormone release inhibiting hormone in acromegaly. Brit. med. J.1, 352–355 (1974)

    PubMed  Google Scholar 

  5. Basser, G.M., Mortimer, C.H., McNeilly, A.S., Thorner, M.O., Batistoni, G.A., Bloom, S.R., Kastrup, K.W., Hanssen, K.F., Hall, R., Coy, D.H., Kastin, A.J.: Long-term infusion of growth hormone release inhibiting hormone in acromegaly: Effects on pituitary and pancreatic hormones. Brit. med. J.4, 622–627 (1974)

    PubMed  Google Scholar 

  6. Besser, G.M., Mortimer, C.H., Carr, D., Bloom, S.R., Lind, T., Hall, R.: Growth hormone release inhibiting hormone (GH-RIH): Prolonged infusions in acromegaly and diabetes mellitus. 56th Annual Meeting of the Endocrine Society (Abstr.) A-157, Atlanta June 12–14, 1974

  7. Besser, G.M., Paxton, A.M., Johnson, S.A.N., Moody, E.J., Mortimer, C.H., Hall, R., Gomez-Pan, A., Schally, A.V., Kastin, A.J., Coy, D.H.: Impairment of platelet function by growth-hormone release inhibiting hormone. LancetI, 1166–1168 (1975)

    Google Scholar 

  8. Bloom, S.R., Mortimer, C.H., Thorner, M.O., Besser, G.M., Hall, R., Gomez-Pan, R., Roy, V.M., Russell, R.C.G., Coy, D.H., Kastin, A.J., Schally, A.V.: Inhibition of gastrin and gastric-acid secretion by growth hormone release inhibiting hormone. LancetII, 1106–1109 (1974)

    Google Scholar 

  9. Born, G.V.R.: Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (Lond.)194, 927–929 (1962)

    PubMed  Google Scholar 

  10. Brazeau, P., Guillemin, R.: Somatostatin: Newcomer from the hypothalamus. New Engl. J. Med.290, 963–964 (1974)

    PubMed  Google Scholar 

  11. Brazeau, P., Rivier, J., Vale, W., Guillemin, R.: Inhibition of growth hormone secretion in the rat by synthetic somatostatin. Endocrinology94, 184–187 (1974)

    PubMed  Google Scholar 

  12. Brecher, G., Cronkite, E.P.: Morphology and enumeration of human blood platelets. J. appl. Physiol.3, 365–377 (1950)

    PubMed  Google Scholar 

  13. Chiang, T.M., Duckworth, W.C., Beachey, E.H., Kang, A.H.: The effect of somatostatin on platelet aggregation. Endocrinology97, 753 (1975)

    PubMed  Google Scholar 

  14. Clauss, A.: Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta haemat.17, 237–246 (1957)

    PubMed  Google Scholar 

  15. Creutzfeldt, W., Lankisch, P.G., Foelsch, U.R.: Hemmung der Sekretin- und Cholezystokinin-Pankreozymin-induzierten Saft- und Enzymsekretion des Pankreas und der Gallenblasenkontraktion beim Menschen durch Somatostatin. Dtsch. med. Wschr.100, 1135–1138 (1975)

    PubMed  Google Scholar 

  16. Copinschi, G., Virasoro, E., Vanhealst, L., Leclercq, R., Golstein, J., L'Hermite, M.: Specific inhibition by somatostatin of growth hormone release after hypoglycaemia in normal man. Clin. Endocr.3, 441–445 (1974)

    Google Scholar 

  17. Dollinger, H.C., Raptis, S., Pfeiffer, E.F.: Effects of somatostatin on exocrine and endocrine pancreatic function stimulated by intestinal hormones in man. Horm. Metab. Res.8, 74–78, 1976

    PubMed  Google Scholar 

  18. Gerich, J.E., Lorenzi, M., Schneider, V., Forsham, P.H.: Effect of somatostatin on plasma glucose and insulin response to glucagon and tolbutamide in man. J. clin. Endocr.39, 1057–1060 (1974)

    PubMed  Google Scholar 

  19. Gerich, J.E., Lorenzi, M., Schneider, V., Karam, J.H., Rivier, J., Guillemin, R., Forsham, P.H.: Effect of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. New Engl. J. Med.291, 544–547 (1974)

    PubMed  Google Scholar 

  20. Gerich, J.E., Lorenzi, M., Schneider, V., Kwan, C.W., Karam, J.H., Guillemin, R., Forsham, P.H.: Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and in insulin-dependent diabetics. Diabetes23, 876–880 (1974)

    PubMed  Google Scholar 

  21. Gerich, J.E., Lorenzi, M., Bier, D.M., Schneider, V., Tsalikian, E., Karam, J.H., Forsham, P.H.: Prevention of human diabetic ketoacidosis by somatostatin. New Engl. J. Med.292, 985–989 (1975)

    PubMed  Google Scholar 

  22. Godal, H.C., Abildgaard, U.: Gelation of soluble fibrin in plasma by ethanol. Scand. J. Haemat.3, 342–350 (1966)

    PubMed  Google Scholar 

  23. Hall, R., Schally, A.V., Evered, D., Kastin, A.J., Mortimer, C.H., Thunbridge, W.M.G., Besser, G.M., Coy, D.H., Goldie, D.J., McNeilly, A.S., Phenekos, C., Weightman, D.: Action of growth hormone release inhibitory hormone in healthy men and in acromegaly. LancetII, 581–584 (1973)

    Google Scholar 

  24. Hartert, H.: Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren. Klin. Wschr.26, 577–583 (1948)

    Google Scholar 

  25. Hertelendy, F., Todd, H., Yeh, M.: Inhibition by somatostatin of prostaglandin stimulated growth hormone release and cyclic AMP accumulation in rat pituitary glands. IRCS2, 1216 (1974)

    Google Scholar 

  26. Ingelfinger, F.J.: Testing drugs: men, mice and baboons (Editorial). New Engl. J. Med.293, 500–501 (1975)

    PubMed  Google Scholar 

  27. Koerker, D.J., Harker, L.A., Goodner, C.J.: Effects of somatostatin on hemostasis in baboons. New Engl. J. Med.293, 476–479 (1975)

    PubMed  Google Scholar 

  28. Lovinger, R., Boryczka, A.T., Shackelford, R., Kaplan, S.L., Ganong, W.F., Grumbach, M.M.: Effect of synthetic somatotropin release inhibiting factor on the increase in plasma growth hormone elicited by L-dopa in the dog. Endocrinology95, 934–946 (1974)

    Google Scholar 

  29. Mattes, P., Raptis, S., Heil, T., Rasche, H., Scheck, R.: Longterm somatostatin treatment of a patient with bleeding ulcer. Horm. Metab. Res.7, 508–511, 1975

    PubMed  Google Scholar 

  30. Meissner, C., Thum, CH., Beischer, W., Winkler, G., Schröder, K.E., Pfeiffer, E.F.: The anti-diabetic action of somatostatin-assessed by artificial pancreas. Diabetes24, 988–996 (1975)

    PubMed  Google Scholar 

  31. Merskey, C., Kleiner, G.J., Johnson, A.J.: Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood28, 1–18 (1966)

    PubMed  Google Scholar 

  32. Mielke, C.H. Jr., Kaneshino, I.A., Mather, J.M., Weiner, J.M., Rapaport, S.I.: The standarized ivy bleeding time and its prolongation by aspirin. Blood34, 204–215 (1969)

    PubMed  Google Scholar 

  33. Mielke, C., Gerich, J.E., Lorenzi, M., Tsalikian, E., Rodvien, R., Forsham, P.H.: The effect of somatostatin on coagulation and platelet function in man. New Engl. J. Med.293, 480–483 (1975)

    PubMed  Google Scholar 

  34. Mortimer, C.H., Carr, D., Lind, T., Bloom, S.R., Mallinson, C.N., Schally, A.V., Tunbridge, W.M.G., Yeomans, L., Coy, D.H., Kastin, A., Besser, G.M., Hall, R.: Effects of growth hormone release inhibiting hormone on circulating glucagon, insulin and growth hormone in normal, diabetic, acromegalic and hypopituitary patients. LancetI, 697–701 (1974)

    Google Scholar 

  35. Mustard, J.F., Packham, M.A.: Factors influencing platelet function: adhesion, release and aggregation. Pharmacol. Rev.22, 97–187 (1970)

    PubMed  Google Scholar 

  36. Parker, D.C., Grossman, L.G., Siler, T.M., Rivier, J., Yen, S.S.C., Guillemin, R.: Inhibition of the sleep-related peak in physiologic human growth hormone release by somatostatin. J. clin. Endocr.38, 496–499 (1974)

    PubMed  Google Scholar 

  37. Raptis, S., Thum, Ch., v. Berger, L., Schröder, K.E., Meissner, C., Schlegel, W.: Inhibition of gastrin secretion by somatostatin. Acta. endocr. (Kbh.), Suppl.193, Abstract 74 (1975)

    Google Scholar 

  38. Raptis, S., Dollinger, H.C., v. Berger, L., Schlegel, W., Schröder, K.E., Pfeiffer, E.F.: Effects of somatostatin on gastric secretion and gastric release in man. Digestion13, 15–27 (1975)

    PubMed  Google Scholar 

  39. Raptis, S., Dollinger, H.C., Rasche, H., Scheck, R., Pfeiffer, E.F.: Long term somatostatin treatment of a patient with persistant amylasemia. (In press)

  40. Ricketts, H.T.: Somatostatin, hormone inhibitor (Editorial) JAMA231, 391–392 (1975)

    PubMed  Google Scholar 

  41. Sakurai, H., Dobbs, R., Unger, R.H.: Somatostatin-induced changes in insulin and glucagon secretion in normal and diabetic dogs. J. clin. Invet.54, 1395–1402 (1974)

    Google Scholar 

  42. Siler, T.M., Vandenberg, G., Yen, S.S.C.: Inhibition of growth hormone release in humans by somatostatin. J. clin. Endocr.37, 632–638 (1973)

    PubMed  Google Scholar 

  43. Triantaphyllopoulos, D.C.: Factor XIII consumption as an indicator of thrombin generation. J. Lab. clin. Med.84, 74–80 (1974)

    PubMed  Google Scholar 

  44. Yen, S.S.C., Siler, T.M., DeVane, G.W.: Effect of somatostatin in patients with acromegaly. New Engl. J. Med.290, 935–938 (1974)

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Serive of Haemostaseology and Departments of Haematology, Endocrinology and Metabolism, Center of Internal Medicine and Pediatrics, University of Ulm/Donau, Germany

    H. Rasche, S. Raptis, R. Scheck & E. F. Pfeiffer

Authors
  1. H. Rasche
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Raptis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Scheck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. F. Pfeiffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rasche, H., Raptis, S., Scheck, R. et al. Coagulation studies and platelet function after somatostatin infusion. Klin Wochenschr 54, 977–982 (1976). https://doi.org/10.1007/BF01468948

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01468948

Schlüsselwörter

Key words

Search

Navigation